Our mission at Naveris is to deliver disruptive technology with the potential to transform cancer detection and improve patient outcomes.
Naveris has developed highly sensitive blood tests for cancers to enable early diagnosis in the general asymptomatic population, real time monitoring of response in patients undergoing treatment, and detection of cancer recurrence in patients in remission.
Our tests use a disruptive proprietary technology to capture and analyze cancer associated DNA in blood plasma that has increased sensitivity compared to existing ctDNA tests.
Our flagship technology is NavDx®, a blood test that analyzes tumor tissue modified DNA in the circulation to detect HPV-related cancer. In clinical studies, NavDx® has established its ability to monitor head & neck cancer recurrence1,2. A positive blood test preceded the detection of recurrence by imaging for 91% of patients, with a median lead-time of 3.9 months1.
Please contact us if you would like to learn more about our technologies and services.
- Clin Cancer Res (2019) 25:4682-90; 2.
- J Clin Oncol (2020) 38(10):1050-1058.